Matching articles for "Topamax"
Issue 1708 · August 5, 2024
Comparison Table: Some Oral Antiseizure Medications (online only)

View the Comparison Table: Some Oral Antiseizure Medications

Med Lett Drugs Ther. 2024 Aug 5; 66(1708):e133-40 doi:10.58347/tml.2024.1708b
View the Comparison Table: Some Oral Antiseizure Medications
Issue 1708 · August 5, 2024
Drugs for Epilepsy

When used for the appropriate seizure type, antiseizure medications (ASMs) are roughly equivalent in efficacy. In addition to the seizure type, the choice of drug is usually based on factors such as ease of…

Med Lett Drugs Ther. 2024 Aug 5; 66(1708):121-8 doi:10.58347/tml.2024.1708a
When used for the appropriate seizure type, antiseizure medications (ASMs) are roughly equivalent in efficacy. In addition to the seizure type, the choice of drug is usually based on factors such as ease of use, spectrum of activity, adverse effects, interactions with other drugs, presence of comorbid conditions, suitability for elderly persons and those with childbearing potential, and cost. Treatment should begin with a single drug, increasing the dosage gradually until seizures are controlled or adverse effects become unacceptable. If seizures persist, expert clinicians generally try at least one and sometimes a second alternative drug as monotherapy before considering use of two drugs at the same time.
Issue 1678 · June 12, 2023
Comparison Table: Some Drugs for Migraine Prevention in Adults (online only)

View the Comparison Table: Some Drugs for Migraine Prevention in Adults

Med Lett Drugs Ther. 2023 Jun 12; 65(1678):e100-2 doi:10.58347/tml.2023.1678c
View the Comparison Table: Some Drugs for Migraine Prevention in Adults
Issue 1678 · June 12, 2023 Free
Drugs for Migraine

An oral nonopioid analgesic is often sufficient for acute treatment of mild to moderate migraine pain without severe nausea or vomiting. A triptan is the drug of choice for treatment of moderate to severe…

Med Lett Drugs Ther. 2023 Jun 12; 65(1678):89-96 doi:10.58347/tml.2023.1678a
An oral nonopioid analgesic is often sufficient for acute treatment of mild to moderate migraine pain without severe nausea or vomiting. A triptan is the drug of choice for treatment of moderate to severe migraine in most patients without vascular disease. Treatment of pain when it is still mild to moderate in intensity improves headache response and reduces the risk of recurrence.
Issue 1639 · December 13, 2021
Drugs for Alcohol Use Disorder

Consumption of alcohol has increased during the COVID-19 pandemic. The Diagnostic and Statistical Manual for Mental Disorders , 5th edition (DSM-5) defines alcohol use disorder (AUD; previously called alcohol…

Med Lett Drugs Ther. 2021 Dec 13; 63(1639):193-8
Consumption of alcohol has increased during the COVID-19 pandemic. The Diagnostic and Statistical Manual for Mental Disorders , 5th edition (DSM-5) defines alcohol use disorder (AUD; previously called alcohol dependence) as meeting ≥2 of the 11 criteria listed in Table 1 in the past year. The lifetime prevalence of AUD in the US population has been estimated to be about 30%. Despite this high prevalence and the associated morbidity, mortality, and costs, only 3 drugs are FDA-approved for treatment of the disorder.
Issue 1636 · November 1, 2021
Atogepant (Qulipta) for Migraine Prevention

Atogepant ( Qulipta – Abbvie), an oral small-molecule calcitonin gene-related peptide (CGRP) receptor antagonist ("gepant"), has been approved by the FDA for prevention of episodic migraine in adults. It is…

Med Lett Drugs Ther. 2021 Nov 1; 63(1636):169-71
Atogepant ( Qulipta – Abbvie), an oral small-molecule calcitonin gene-related peptide (CGRP) receptor antagonist ("gepant"), has been approved by the FDA for prevention of episodic migraine in adults. It is the second oral CGRP receptor antagonist to be approved in the US for this indication; the first was rimegepant (Nurtec ODT) , which is also approved for acute treatment of migraine. Parenteral CGRP monoclonal antibodies are approved for prevention of migraine (see Table 3).
Issue 1630 · August 9, 2021
Fenfluramine (Fintepla) for Dravet Syndrome

The FDA has approved fenfluramine oral solution ( Fintepla – Zogenix) for treatment of seizures in patients ≥2 years old with Dravet syndrome. It is the third drug to be approved for this indication.…

Med Lett Drugs Ther. 2021 Aug 9; 63(1630):126-8
The FDA has approved fenfluramine oral solution ( Fintepla – Zogenix) for treatment of seizures in patients ≥2 years old with Dravet syndrome. It is the third drug to be approved for this indication. Stiripentol (Diacomit) and cannabidiol (Epidiolex) , a purified product derived from marijuana, were approved earlier.
Issue 1620 · March 24, 2021
Stiripentol (Diacomit) for Dravet Syndrome (online only)

The FDA has approved stiripentol (Diacomit – Biocodex) for treatment of seizures in patients ≥2 years old with Dravet syndrome who are also taking clobazam (Onfi) . Stiripentol, which has been available in…

Med Lett Drugs Ther. 2021 Mar 24; 63(1620):e1-3
The FDA has approved stiripentol (Diacomit – Biocodex) for treatment of seizures in patients ≥2 years old with Dravet syndrome who are also taking clobazam (Onfi) . Stiripentol, which has been available in Europe, Canada, and Japan for many years, is the second drug to be approved in the US for this indication; cannabidiol oral solution (Epidiolex) , a purified marijuana product, was the first.
Issue 1608 · October 5, 2020
Drugs for Migraine

An oral nonopioid analgesic is often sufficient for acute treatment of mild to moderate migraine headache without severe nausea or vomiting. A triptan is the drug of choice for treatment of moderate to severe…

Med Lett Drugs Ther. 2020 Oct 5; 62(1608):153-60
An oral nonopioid analgesic is often sufficient for acute treatment of mild to moderate migraine headache without severe nausea or vomiting. A triptan is the drug of choice for treatment of moderate to severe migraine headache pain in most patients without vascular disease. Early treatment of pain when it is still mild to moderate in intensity improves headache response and reduces the risk of recurrence.
Issue 1599 · June 1, 2020
Eptinezumab (Vyepti) for Migraine Prevention

The FDA has approved eptinezumab-jjmr ( Vyepti – Lundbeck), a calcitonin gene-related peptide (CGRP) antagonist administered IV once every 3 months, for migraine prevention in adults. It is the fourth…

Med Lett Drugs Ther. 2020 Jun 1; 62(1599):85-7
The FDA has approved eptinezumab-jjmr ( Vyepti – Lundbeck), a calcitonin gene-related peptide (CGRP) antagonist administered IV once every 3 months, for migraine prevention in adults. It is the fourth monoclonal antibody to be approved for this indication; erenumab ( Aimovig) , fremanezumab (Ajovy) , and galcanezumab ( Emgality) , which are all given subcutaneously once monthly (fremanezumab can also be given once every 3 months), were approved earlier.
Issue 1559 · November 5, 2018
Fremanezumab (Ajovy) and Galcanezumab (Emgality) for Migraine Prevention

The FDA has approved two subcutaneously injected calcitonin gene-related peptide (CGRP) antagonists, fremanezumab-vfrm ( Ajovy – Teva) and galcanezumab-gnlm ( Emgality – Lilly), for migraine prevention in…

Med Lett Drugs Ther. 2018 Nov 5; 60(1559):177-80
The FDA has approved two subcutaneously injected calcitonin gene-related peptide (CGRP) antagonists, fremanezumab-vfrm ( Ajovy – Teva) and galcanezumab-gnlm ( Emgality – Lilly), for migraine prevention in adults. Fremanezumab and galcanezumab are the second and third subcutaneously injected monoclonal antibodies that target the CGRP pathway to be approved by the FDA for this indication; erenumab-aooe (Aimovig) , which targets the CGRP receptor, was the first.
Issue 1559 · November 5, 2018
Cannabidiol (Epidiolex) for Epilepsy

The FDA has approved cannabidiol oral solution ( Epidiolex – Greenwich Biosciences) for treatment of seizures associated with Dravet syndrome or Lennox-Gastaut syndrome in patients ≥2 years old.…

Med Lett Drugs Ther. 2018 Nov 5; 60(1559):182-4
The FDA has approved cannabidiol oral solution ( Epidiolex – Greenwich Biosciences) for treatment of seizures associated with Dravet syndrome or Lennox-Gastaut syndrome in patients ≥2 years old. Cannabidiol (CBD) is a cannabinoid constituent of the marijuana plant (Cannabis sativa) . It is the first natural marijuana product to be approved by the FDA for any indication and the first drug to be approved in the US for treatment of Dravet syndrome. Stiripentol (Diacomit) , which is not a marijuana product, was also recently approved by the FDA for treatment of Dravet syndrome in combination with clobazam ( Onfi) and will be reviewed in a future issue.
Issue 1549 · June 18, 2018
Erenumab (Aimovig) for Migraine Prevention

The FDA has approved erenumab-aooe ( Aimovig – Amgen/Novartis), a once-monthly, subcutaneously-injected, monoclonal antibody against the calcitonin gene-related peptide receptor, for preventive treatment of…

Med Lett Drugs Ther. 2018 Jun 18; 60(1549):101-3
The FDA has approved erenumab-aooe ( Aimovig – Amgen/Novartis), a once-monthly, subcutaneously-injected, monoclonal antibody against the calcitonin gene-related peptide receptor, for preventive treatment of migraine in adults. It is the first drug in its class to be approved by the FDA.
Issue 1526 · July 31, 2017
Drugs for Epilepsy

Treatment of epilepsy should begin with a single antiepileptic drug (AED), increasing its dosage gradually until seizures are controlled or adverse effects become intolerable. If seizures persist, specialists…

Med Lett Drugs Ther. 2017 Jul 31; 59(1526):121-30
Treatment of epilepsy should begin with a single antiepileptic drug (AED), increasing its dosage gradually until seizures are controlled or adverse effects become intolerable. If seizures persist, specialists generally recommend trying at least one and sometimes a second alternative drug as monotherapy before considering use of two drugs concurrently. When used for the appropriate seizure type, AEDs are roughly equivalent in efficacy. Drug choice is usually based on factors such as ease of use, adverse effects, drug interactions, presence of comorbidities, and cost.
Issue 1526 · July 31, 2017
Comparison Table: Some Oral Antiepileptic Drugs (online only)

View the Comparison Table: Some Oral Antiepileptic Drugs

Med Lett Drugs Ther. 2017 Jul 31; 59(1526):e130-6
View the Comparison Table: Some Oral Antiepileptic Drugs
Issue 1517 · March 27, 2017
Exablate Neuro for Essential Tremor

The FDA has approved use of Exablate Neuro (Insightec) for unilateral thalamotomy to treat medication-refractory essential tremor in patients ≥22 years old. Exablate Neuro uses magnetic resonance-guided…

Med Lett Drugs Ther. 2017 Mar 27; 59(1517):52-3
The FDA has approved use of Exablate Neuro (Insightec) for unilateral thalamotomy to treat medication-refractory essential tremor in patients ≥22 years old. Exablate Neuro uses magnetic resonance-guided focused ultrasound (MRgFUS) to create lesions in the ventral intermediate nucleus of the thalamus. MRgFUS is also approved in the US for treatment of uterine fibroids and for pain palliation of bone metastases.
Issue 1514 · February 13, 2017
Drugs for Migraine

An oral nonopioid analgesic may be sufficient for treatment of mild to moderate migraine without severe nausea or vomiting. A triptan is the drug of choice for treatment of moderate to severe migraine. Use of…

Med Lett Drugs Ther. 2017 Feb 13; 59(1514):27-32
An oral nonopioid analgesic may be sufficient for treatment of mild to moderate migraine without severe nausea or vomiting. A triptan is the drug of choice for treatment of moderate to severe migraine. Use of a triptan early in an attack when pain is still mild to moderate in intensity improves headache response and reduces recurrence rates.
Issue 1514 · February 13, 2017
Comparison Table: Some Drugs for Migraine Prevention in Adults (online only)

View the Comparison Table: Some Drugs for Migraine Prevention in Adults

Med Lett Drugs Ther. 2017 Feb 13; 59(1514):e31-2
View the Comparison Table: Some Drugs for Migraine Prevention in Adults
Issue 1457 · December 8, 2014 Free
In Brief: Topiramate Extended-Release Capsules (Qudexy XR) (online only)

The FDA has approved a new extended-release capsule formulation of topiramate ( Qudexy XR – Upsher Smith), which can be opened and sprinkled on food for patients who have difficulty swallowing tablets or…

Med Lett Drugs Ther. 2014 Dec 8; 56(1457):e126
The FDA has approved a new extended-release capsule formulation of topiramate ( Qudexy XR – Upsher Smith), which can be opened and sprinkled on food for patients who have difficulty swallowing tablets or capsules, for treatment of epilepsy. Qudexy XR was marketed as a branded drug in March 2014 and as a generic drug four months later. An earlier extended-release formulation (Trokendi XR) must be swallowed whole. Trokendi XR is approved for initial monotherapy in patients ≥10 years old with partial-onset seizures or primary generalized tonic-clonic seizures and for adjunctive therapy in patients ≥6 years old with partial-onset seizures, primary generalized tonic-clonic seizures, or seizures associated with Lennox-Gastaut syndrome. Qudexy XR has been approved for the same indications, but the indication for adjunctive therapy has been extended to children ≥2 years old. Topiramate has been available for many years in immediate-release formulations ( Topamax , and others) for the same indications for patients ≥2 years old. Trokendi XR and Qudexy XR both appear to be bioequivalent to immediate-release formulations of topiramate; whether they are bioequivalent to one another has not been established. Download complete U.S. English article
Issue 136 · December 1, 2013
Drugs for Migraine

Treatment of migraine in the emergency department, which may involve use of intravenous drugs, is not discussed here.

Treat Guidel Med Lett. 2013 Dec; 11(136):107-12
Treatment of migraine in the emergency department, which may involve use of intravenous drugs, is not discussed here.
Issue 1428 · October 28, 2013
Topiramate Extended-Release (Trokendi XR) for Epilepsy

The FDA has approved a once-daily extended-release (ER) formulation of the antiepileptic topiramate ( Trokendi XR – Supernus) for initial monotherapy in patients ≥10 years old with partial onset seizures…

Med Lett Drugs Ther. 2013 Oct 28; 55(1428):87-8
The FDA has approved a once-daily extended-release (ER) formulation of the antiepileptic topiramate ( Trokendi XR – Supernus) for initial monotherapy in patients ≥10 years old with partial onset seizures or primary generalized tonic-clonic seizures and for adjunctive therapy in patients ≥6 years old with partial onset seizures, primary generalized tonic-clonic seizures, or seizures associated with Lennox-Gastaut syndrome. Topiramate has been available for many years as an immediate-release (IR) formulation ( Topamax , and generics) for the same indications in patients ≥2 years old
Issue 126 · February 1, 2013
Drugs for Epilepsy

Treatment of epilepsy should begin with a single drug, increasing the dosage gradually until seizures are controlled or adverse effects become unacceptable. If seizures persist, expert clinicians generally…

Treat Guidel Med Lett. 2013 Feb; 11(126):9-18
Treatment of epilepsy should begin with a single drug, increasing the dosage gradually until seizures are controlled or adverse effects become unacceptable. If seizures persist, expert clinicians generally prescribe at least one and sometimes a second alternative drug as monotherapy before considering use of two drugs at the same time. When used for the appropriate seizure type, antiepileptic drugs are roughly equivalent in efficacy. The choice of drug is usually based on factors such as ease of use, adverse effects, interactions with other drugs, presence of comorbid conditions and cost.
Issue 1398 · September 3, 2012
Two Drugs for Weight Loss

In 2013 the FDA approved one new drug and a new combination of 2 old drugs as adjuncts to lifestyle changes for chronic weight management. Lorcaserin (lor-ca-SER-in; Belviq – Arena/Esai) is a selective…

Med Lett Drugs Ther. 2012 Sep 3; 54(1398):69-71
In 2013 the FDA approved one new drug and a new combination of 2 old drugs as adjuncts to lifestyle changes for chronic weight management. Lorcaserin (lor-ca-SER-in; Belviq – Arena/Esai) is a selective serotonin 2C receptor agonist. Qsymia (Vivus) is a fixed-dose combination of the weight-loss drug phentermine and an extended-release (ER) formulation of topiramate. The new products are approved for use in obese patients (body mass index [BMI] of ≥30 kg/m 2 ) and for patients who are overweight (BMI ≥27 kg/m 2 ) and have one weight-related risk factor such as hypertension, dyslipidemia or type 2 diabetes.
Issue 1397 · August 20, 2012
Ezogabine (Potiga) for Epilepsy

The FDA has approved ezogabine (ee-ZOE-ga-been; Potiga – GSK/Valeant) for oral adjunctive treatment of partial-onset seizures in adults. Ezogabine is available in Europe as retigabine (Trobalt) .

Med Lett Drugs Ther. 2012 Aug 20; 54(1397):65-7
The FDA has approved ezogabine (ee-ZOE-ga-been; Potiga – GSK/Valeant) for oral adjunctive treatment of partial-onset seizures in adults. Ezogabine is available in Europe as retigabine (Trobalt) .
Issue 1385 · March 5, 2012
Clobazam (Onfi) for Lennox-Gastaut Syndrome

Clobazam ( Onfi – Lundbeck), an oral benzodiazepine, has been approved by the FDA for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients ≥2 years old. It has been…

Med Lett Drugs Ther. 2012 Mar 5; 54(1385):18-9
Clobazam ( Onfi – Lundbeck), an oral benzodiazepine, has been approved by the FDA for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients ≥2 years old. It has been available in Canada (Frisium) and other countries for years for treatment of anxiety and many types of epilepsy.
Issue 104 · April 1, 2011
Diet, Drugs and Surgery for Weight Loss

Adults with a body mass index (BMI=kg/m 2 ) of 25-<30 are considered overweight; those with a BMI of ≥30 are considered obese.

Treat Guidel Med Lett. 2011 Apr; 9(104):17-22
Adults with a body mass index (BMI=kg/m 2 ) of 25-<30 are considered overweight; those with a BMI of ≥30 are considered obese.
Issue 102 · February 1, 2011
Drugs for Migraine

Drugs for treatment of migraine are listed in Table 2 on page 9. Drugs for prevention of migraine are listed in Table 3 on page 10. Treatment of migraine in the emergency room, which may involve use of…

Treat Guidel Med Lett. 2011 Feb; 9(102):7-12
Drugs for treatment of migraine are listed in Table 2 on page 9. Drugs for prevention of migraine are listed in Table 3 on page 10. Treatment of migraine in the emergency room, which may involve use of intravenous drugs, is not included here.
Issue 1356 · January 24, 2011
Botulinum Toxin for Chronic Migraine

The FDA has approved injection of onabotulinumtoxinA ( Botox – Allergan) for prevention of headaches in adult patients with chronic migraine (≥15 headache days/month for ≥3 months). It is the first drug…

Med Lett Drugs Ther. 2011 Jan 24; 53(1356):7
The FDA has approved injection of onabotulinumtoxinA ( Botox – Allergan) for prevention of headaches in adult patients with chronic migraine (≥15 headache days/month for ≥3 months). It is the first drug approved for treatment of this indication. Botox is also FDA-approved for treatment of upper limb spasticity, axillary hyperhidrosis, cervical dystonia, blepharospasm and strabismus, and for cosmetic reduction of wrinkles.
Issue 92 · April 1, 2010
Drugs for Pain

Pain can be acute or chronic. Chronic pain has been broadly classified into two types: nociceptive and neuropathic. Nociceptive pain can be treated with nonopioid analgesics or opioids. Neuropathic pain is…

Treat Guidel Med Lett. 2010 Apr; 8(92):25-34
Pain can be acute or chronic. Chronic pain has been broadly classified into two types: nociceptive and neuropathic. Nociceptive pain can be treated with nonopioid analgesics or opioids. Neuropathic pain is less responsive to opioids; adjuvant medicines such as antidepressants and anticonvulsants are often used to treat neuropathic pain. Combining different types of analgesics may provide an additive analgesic effect without increasing adverse effects.
Issue 1332 · February 22, 2010
Vigabatrin (Sabril) for Epilepsy

The FDA has approved vigabatrin (vye gá ba trin; Sabril – Lundbeck) for oral use as add-on therapy for complex partial seizures in adults who are refractory to several antiepileptic drugs and as monotherapy…

Med Lett Drugs Ther. 2010 Feb 22; 52(1332):14-6
The FDA has approved vigabatrin (vye gá ba trin; Sabril – Lundbeck) for oral use as add-on therapy for complex partial seizures in adults who are refractory to several antiepileptic drugs and as monotherapy for infantile spasms. Vigabatrin has been available in other countries for many years. Because of its potential for retinal toxicity, it will be available in the US only through a restricted distribution program called SHARE (Support, Help and Resources for Epilepsy). Prescribers and pharmacists distributing the drug must register, and patients must undergo visual field testing.
Issue 1323 · October 19, 2009
Generic Drugs Revisited

The equivalence of generic drugs to their brand-name precursors continues to be controversial. The last Medical Letter review of this subject (2002) concluded that well-documented therapeutic inequivalence…

Med Lett Drugs Ther. 2009 Oct 19; 51(1323):81-2
The equivalence of generic drugs to their brand-name precursors continues to be controversial. The last Medical Letter review of this subject (2002) concluded that well-documented therapeutic inequivalence between brand-name and FDA-approved generic drugs had not been reported. Is that still true? New data have become available for some drugs.
Issue 1315 · June 29, 2009
Lacosamide for Epilepsy

The FDA has approved lacosamide ( Vimpat - UCB Pharma) for oral or intravenous (IV) use as add-on therapy in adults with partial-onset seizures.

Med Lett Drugs Ther. 2009 Jun 29; 51(1315):50-2
The FDA has approved lacosamide ( Vimpat - UCB Pharma) for oral or intravenous (IV) use as add-on therapy in adults with partial-onset seizures.
Issue 1307 · March 9, 2009
Rufinamide (Banzel) for Epilepsy

Rufinamide (Banzel - Eisai), a triazole derivative structurally unrelated to other marketed antiepileptic drugs (AEDs), has been approved by the FDA for treatment of seizures associated with Lennox-Gastaut…

Med Lett Drugs Ther. 2009 Mar 9; 51(1307):18-20
Rufinamide (Banzel - Eisai), a triazole derivative structurally unrelated to other marketed antiepileptic drugs (AEDs), has been approved by the FDA for treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients ≥4 years old.
Issue 73 · September 1, 2008
Drugs for Tobacco Dependence

Peptic ulcers caused by treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) are mainly gastric ulcers. The greater the number of office visits and the longer the counseling time, the higher the…

Treat Guidel Med Lett. 2008 Sep; 6(73):61-5
Peptic ulcers caused by treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) are mainly gastric ulcers. The greater the number of office visits and the longer the counseling time, the higher the smoking cessation rates have been.
Issue 70 · June 1, 2008
Drugs for Epilepsy

Treatment of epilepsy should begin with a single drug, increasing the dosage gradually until seizures are controlled or adverse effects become unacceptable. If seizures continue and further dosage increases…

Treat Guidel Med Lett. 2008 Jun; 6(70):37-46
Treatment of epilepsy should begin with a single drug, increasing the dosage gradually until seizures are controlled or adverse effects become unacceptable. If seizures continue and further dosage increases appear inadvisable because of adverse effects, most Medical Letter consultants generally prescribe at least one and sometimes a second alternative drug as monotherapy before considering use of two drugs at the same time. Most antiepileptic drugs initially approved by the FDA only as adjunctive therapy for partial seizures may also be effective for other types of seizures and as monotherapy. Studies suggest that when used for the appropriate seizure type, antiepileptic drugs are roughly equivalent in efficacy. The choice of a drug is usually based on factors such as ease of use, adverse effects and cost.
Issue 68 · April 1, 2008
Diet, Drugs and Surgery for Weight Loss

Losing even a small amount of weight and increasing physical activity can prevent some of the complications of obesity, particularly type 2 diabetes. Diet and exercise are the preferred methods for losing…

Treat Guidel Med Lett. 2008 Apr; 6(68):23-7
Losing even a small amount of weight and increasing physical activity can prevent some of the complications of obesity, particularly type 2 diabetes. Diet and exercise are the preferred methods for losing weight but are associated with high long-term failure rates. Drugs may help some patients, but all currently available drugs for weight reduction have drawbacks. Gastric surgery can produce marked weight loss in the severely obese, but long-term data on safety are limited.
Issue 67 · March 1, 2008
Drugs for Migraine

Some drugs for treatment of migraine attacks are listed in table 2 on page 18. Drugs for prevention of migraine are listed in table 3 on page 20. Treatment of migraine in the emergency room, which may involve…

Treat Guidel Med Lett. 2008 Mar; 6(67):17-22
Some drugs for treatment of migraine attacks are listed in table 2 on page 18. Drugs for prevention of migraine are listed in table 3 on page 20. Treatment of migraine in the emergency room, which may involve use of intravenous drugs, is not included here.
Issue 39 · November 1, 2005
Drugs for Epilepsy

Treatment of epilepsy should begin with a single drug, increasing the dosage gradually until seizures are controlled or adverse effects become unacceptable. If seizures continue and further dosage increases…

Treat Guidel Med Lett. 2005 Nov; 3(39):75-82
Treatment of epilepsy should begin with a single drug, increasing the dosage gradually until seizures are controlled or adverse effects become unacceptable. If seizures continue and further dosage increases appear inadvisable because of adverse effects, most Medical Letter consultants generally prescribe at least one and sometimes a second alternative drug as monotherapy before considering use of two drugs at the same time. Most antiepileptic drugs initially approved by the FDA only as adjunctive therapy for partial seizures may also be effective for other types of seizures and as monotherapy.
Issue 1201 · January 31, 2005
Topiramate (Topamax) for Prevention of Migraine

Patients with frequent, severe or disabling migraine headaches may benefit from taking a drug to prevent the attacks. Beta-blockers traditionally have been the prophylactic treatment of choice, but in recent…

Med Lett Drugs Ther. 2005 Jan 31; 47(1201):9-10
Patients with frequent, severe or disabling migraine headaches may benefit from taking a drug to prevent the attacks. Beta-blockers traditionally have been the prophylactic treatment of choice, but in recent years some antiepileptic drugs such as valproate ( Depakote , and others) and topiramate (Topamax) have also been used for this indication. Valproate was approved by the FDA for such use in 1996. Now topiramate has also been approved.
Issue 1199 · January 3, 2005
Acamprosate (Campral) for Alcoholism

Acamprosate calcium ( Campral - Forest) is now being marketed for oral use to maintain abstinence from alcohol. It has been used in France and other countries since 1989.

Med Lett Drugs Ther. 2005 Jan 3; 47(1199):1-3
Acamprosate calcium ( Campral - Forest) is now being marketed for oral use to maintain abstinence from alcohol. It has been used in France and other countries since 1989.
Issue 25 · September 1, 2004
Drugs for Migraine

Drugs for treatment of migraine attacks are listed in the table on page 64. All of the oral drugs are most effective if taken early in an attack when the pain is mild (H Christoph-Diener et al, Neurology 2004;…

Treat Guidel Med Lett. 2004 Sep; 2(25):63-6
Drugs for treatment of migraine attacks are listed in the table on page 64. All of the oral drugs are most effective if taken early in an attack when the pain is mild (H Christoph-Diener et al, Neurology 2004; 63:520). Drugs for prevention of migraine are listed in the table on page 65. Treatment of migraine in the emergency room, which may involve use of intravenous drugs, is not included here.
Issue 23 · July 1, 2004
Drugs for Pain

Three types of analgesic drugs are available: non-opioids, including aspirin, other nonsteroidal anti-inflammatory drugs (NSAIDs) and acetaminophen; opioids; and adjuvant drugs that are not usually thought of…

Treat Guidel Med Lett. 2004 Jul; 2(23):47-54
Three types of analgesic drugs are available: non-opioids, including aspirin, other nonsteroidal anti-inflammatory drugs (NSAIDs) and acetaminophen; opioids; and adjuvant drugs that are not usually thought of as analgesics, such as antidepressants, which can act as adjuvants when given with NSAIDs or opioids, or have analgesic activity of their own in some types of pain. Combining two different types of analgesics may provide an additive analgesic effect without necessarily increasing adverse effects.
Issue 16 · December 1, 2003
Diet, Drugs and Surgery for Weight Loss

The latest definitions of overweight and obesity are based on body mass index (BMI). The BMI is calculated by dividing the weight in kilograms by the square of the height in meters (kg/m 2 ). More than half of…

Treat Guidel Med Lett. 2003 Dec; 1(16):101-6
The latest definitions of overweight and obesity are based on body mass index (BMI). The BMI is calculated by dividing the weight in kilograms by the square of the height in meters (kg/m 2 ). More than half of American adults are considered overweight with a BMI of ≥25, and about one third are obese with a BMI of ≥30. All ages seem to be affected; the proportion of children and adolescents who are overweight has more than doubled in the past 25 years. There is no lack of effort to treat obesity: drugs, diets and programs to change lifestyle are the basis for a large and flourishing industry. The frequent failure of diet and drug treatment sometimes leads to recommendations for surgery, usually restricted to those with a BMI ≥40.
Issue 9 · May 1, 2003
Drugs for Epilepsy

Treatment of epilepsy should begin with a single drug, increasing the dosage gradually until seizures are controlled or adverse effects become unacceptable. If seizures continue and further dosage increases…

Treat Guidel Med Lett. 2003 May; 1(9):57-64
Treatment of epilepsy should begin with a single drug, increasing the dosage gradually until seizures are controlled or adverse effects become unacceptable. If seizures continue and further dosage increases appear inadvisable because of adverse effects, most Medical Letter consultants generally prescribe at least one and sometimes a second alternative drug as monotherapy before considering use of two drugs at the same time. Most antiepileptic drugs initially approved by the FDA only for adjunctive therapy are probably also effective as monotherapy. Many of the drugs used to treat epilepsy interact with each other (see table beginning on page 63) and with other drugs; for interactions with other drugs, see The Medical Letter Handbook of Adverse Drug Interactions, 2003. The treatment of status epilepticus is not included here.
Issue 1094 · December 11, 2000
Valproate and Other Anticonvulsants For Psychiatric Disorders

Anticonvulsants are now widely used for treatment of psychiatric illnesses, particularly bipolar disorder. Lithium is the standard drug for treatment of bipolar disorder, but it can cause severe toxicity,…

Med Lett Drugs Ther. 2000 Dec 11; 42(1094):114-5
Anticonvulsants are now widely used for treatment of psychiatric illnesses, particularly bipolar disorder. Lithium is the standard drug for treatment of bipolar disorder, but it can cause severe toxicity, serum concentrations must be monitored, and it is not effective in some patients.
Issue 1089 · October 2, 2000
Zonisamide (Zonegran) For Epilepsy

Zonisamide ( Zonegran - Elan Pharma), a sulfonamide chemically unrelated to other antiepileptic drugs, has been approved by the FDA for adjunctive use in adults with partial seizures. Zonisamide has been…

Med Lett Drugs Ther. 2000 Oct 2; 42(1089):94-5
Zonisamide ( Zonegran - Elan Pharma), a sulfonamide chemically unrelated to other antiepileptic drugs, has been approved by the FDA for adjunctive use in adults with partial seizures. Zonisamide has been available in Japan for more than 10 years.
Issue 1076 · April 17, 2000
Two New Drugs for Epilepsy

Oxcarbazepine, which is chemically similar to carbamazepine, and levetiracetam, a pyrrolidine acetamide chemically unrelated to other antiepileptic drugs, are the sixth and seventh drugs approved by the US…

Med Lett Drugs Ther. 2000 Apr 17; 42(1076):33-5
Oxcarbazepine, which is chemically similar to carbamazepine, and levetiracetam, a pyrrolidine acetamide chemically unrelated to other antiepileptic drugs, are the sixth and seventh drugs approved by the US Food and Drug Administration in the last five years for oral use in partial seizures.
Issue 1001 · May 23, 1997
Topiramate for Epilepsy

Topiramate ( Topamax - Ortho-McNeil) has been approved by the US Food and Drug Administration (FDA) for oral use as an adjunct to other drugs in adult patients with partial seizures. Since this diagnostic…

Med Lett Drugs Ther. 1997 May 23; 39(1001):51-2
Topiramate ( Topamax - Ortho-McNeil) has been approved by the US Food and Drug Administration (FDA) for oral use as an adjunct to other drugs in adult patients with partial seizures. Since this diagnostic category includes the largest number of patients with refractory epilepsy, new drugs with antiepileptic activity are usually tried first for this indication. Topiramate (toe pyre' a mate) is a structurally unique agent chemically related to the D-enantiomer of fructose.